Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium

Status Recruiting

Clinical Trial Summary

Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function. MRI can give more detailed information about the heart by using a contrast 'dye' that is injected into a vein during the scan. This can highlight abnormal areas within the heart. Current contrast dyes help identify scarring within the heart, which is useful in people who have had heart attacks. The investigators plan to test new contrast dye containing manganese, which works differently to current agents. They believe it will provide unique insight into how the heart works.

There are many different causes of heart problems and the investigators plan to use this new contrast agent to scan three patient groups; (i) heart disease caused by heart attacks, (ii) heart disease with abnormal thickening of the heart muscle, and (iii) heart disease where the heart becomes stretched and enlarged. Healthy volunteers will be scanned for comparison.

The study will be carried out at the Royal Infirmary of Edinburgh. Adults between 18 and 65 with stable heart failure can be considered. Women who may be pregnant are unable to participate, as is anyone who has some types of metal in their body, as these people can't have an MRI scan safely. All participants will have 2 MRI scans lasting about an hour each, at least 2 days apart. Some participants will be have 4 MRI scans, over a longer time period. The investigators will also take some blood samples and record a tracing of the heart rhythm and will ensure there are no abnormal side-effects by telephone follow up.

The investigators believe this new agent has potential to better measure disease in the heart, improve the ability to establish the cause of heart disease and help monitor the disease over time as well as guide future treatment for individual patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03607669
Study type	Observational
Source	University of Edinburgh
Contact	Nicholas B Spath
Phone	0131 242 6515
Email	nick.spath@ed.ac.uk
Status	Recruiting
Phase
Start date	June 1, 2018
Completion date	December 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03249272` - Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve	Phase 4
Recruiting	`NCT03846297` - Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
Completed	`NCT02806479` - Hypertrophic Cardiomyopathy Pilot Study
Active, not recruiting	`NCT01225978` - Refining Information Technology Support for Genetics in Medicine	N/A
Completed	`NCT00001632` - Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease	N/A
Completed	`NCT00001534` - Long Term Effects of Enalapril and Losartan on Genetic Heart Disease	N/A
Enrolling by invitation	`NCT04050579` - OPIE in the Thin Interventricular Septum	N/A
Completed	`NCT03537183` - Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?	N/A
Completed	`NCT02590809` - Hypertrophic Cardiomyopathy Symptom Release by BX1514M	Phase 2
Completed	`NCT00001396` - Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...	Phase 1
Active, not recruiting	`NCT03723655` - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM	Phase 2/Phase 3
Completed	`NCT05135871` - Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects	Phase 1
Completed	`NCT04129905` - Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies	N/A
Recruiting	`NCT03061994` - Metabolomic Study of All-age Cardiomyopathy	N/A
Completed	`NCT02234336` - Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Recruiting	`NCT00221832` - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	N/A
Not yet recruiting	`NCT03706001` - Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression	N/A
Recruiting	`NCT06169358` - Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
Not yet recruiting	`NCT04090437` - HCM-AF Ablation With ACUTUS	N/A
Completed	`NCT04402268` - Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.